Will oversee the compliant manufacture and quality assurance of phage-based therapeutics
AmpliPhi Biosciences Corporation, a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, has appointed Dr Alexander Gaidamaka as the new Vice President of Chemistry, Manufacturing and Control.
Dr Gaidamaka brings extensive experience to the company, with more than 25 years in the life sciences sector. Prior to his role at AmpliPhi, he served as CEO and CSO of Personalized OncoTherapeutics. He has held executive R&D, product development and quality control roles at Pharma Green, Merial, Sanofi Pasteur, Bioniche Life Sciences and Biopharm JSC.
'As we drive our bacteriophage-based pipeline towards clinical development, we are expanding our senior team to add certain critical skills,' said M Scott Salka, CEO of AmpliPhi Biosciences. 'Alexander brings decades of experience and leadership to his role of overseeing the compliant manufacture and quality assurance of our phage-based therapeutics.'